+

WO1997046673A3 - Inhibition de la replication du vih-1 au moyen de l'expression d'arn antisens - Google Patents

Inhibition de la replication du vih-1 au moyen de l'expression d'arn antisens Download PDF

Info

Publication number
WO1997046673A3
WO1997046673A3 PCT/EP1997/002952 EP9702952W WO9746673A3 WO 1997046673 A3 WO1997046673 A3 WO 1997046673A3 EP 9702952 W EP9702952 W EP 9702952W WO 9746673 A3 WO9746673 A3 WO 9746673A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
replication
inhibition
antisense rna
rna expression
Prior art date
Application number
PCT/EP1997/002952
Other languages
English (en)
Other versions
WO1997046673A2 (fr
Inventor
Ernst Boehnlein
Sonia Escaich
Heini Ilves
Gabor Veres
Original Assignee
Ciba Geigy Ag
Systemix Inc
Ernst Boehnlein
Sonia Escaich
Heini Ilves
Gabor Veres
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag, Systemix Inc, Ernst Boehnlein, Sonia Escaich, Heini Ilves, Gabor Veres filed Critical Ciba Geigy Ag
Priority to JP10500237A priority Critical patent/JP2001502884A/ja
Priority to IL12703897A priority patent/IL127038A0/xx
Priority to US09/194,300 priority patent/US6776986B1/en
Priority to NZ333190A priority patent/NZ333190A/en
Priority to EP97928151A priority patent/EP0914423A2/fr
Priority to AU32558/97A priority patent/AU717233B2/en
Publication of WO1997046673A2 publication Critical patent/WO1997046673A2/fr
Publication of WO1997046673A3 publication Critical patent/WO1997046673A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des nouvelles séquences antisens ayant pour cible des portions à épissage simple ou non épissées d'un produit de transcription d'ARNm provenant du provirus du VIH de type 1 (VIH-1), éventuellement exprimées en même temps qu'une protéine du VIH-1 mutante, transdominante et inhibitrice. Ces séquences sont utiles dans le traitement de l'infection à VIH-1.
PCT/EP1997/002952 1996-06-06 1997-06-06 Inhibition de la replication du vih-1 au moyen de l'expression d'arn antisens WO1997046673A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP10500237A JP2001502884A (ja) 1996-06-06 1997-06-06 アンチセンスｒｎａ発現によるｈｉｖ―１複製の阻害
IL12703897A IL127038A0 (en) 1996-06-06 1997-06-06 Inhibition of hiv-1 replication by antisense rna expression
US09/194,300 US6776986B1 (en) 1996-06-06 1997-06-06 Inhibition of HIV-1 replication by antisense RNA expression
NZ333190A NZ333190A (en) 1996-06-06 1997-06-06 Inhibition of HIV-1 replication by antisense RNA expression using transduced hematopoietic cells
EP97928151A EP0914423A2 (fr) 1996-06-06 1997-06-06 Inhibition de la replication du vih-1 au moyen de l'expression d'arn antisens
AU32558/97A AU717233B2 (en) 1996-06-06 1997-06-06 Inhibition of HIV-1 replication by antisense RNA expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1923296P 1996-06-06 1996-06-06
US60/019,232 1996-06-06

Publications (2)

Publication Number Publication Date
WO1997046673A2 WO1997046673A2 (fr) 1997-12-11
WO1997046673A3 true WO1997046673A3 (fr) 1998-01-15

Family

ID=21792127

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/002952 WO1997046673A2 (fr) 1996-06-06 1997-06-06 Inhibition de la replication du vih-1 au moyen de l'expression d'arn antisens

Country Status (7)

Country Link
EP (1) EP0914423A2 (fr)
JP (1) JP2001502884A (fr)
AU (1) AU717233B2 (fr)
CA (1) CA2254819A1 (fr)
IL (1) IL127038A0 (fr)
NZ (1) NZ333190A (fr)
WO (1) WO1997046673A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
DE60045932D1 (de) * 2000-09-01 2011-06-16 Gen Probe Inc HIV-1-Sequenzverstärkung zur Erkennung von Sequenzen in Zusammenhang mit Wirkstoffresistenz-Mutationen
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
JP5461460B2 (ja) * 2011-03-01 2014-04-02 ジェン−プローブ・インコーポレーテッド 薬剤耐性突然変異と関連する配列検出のためのｈｉｖ−１配列の増幅
JP5461459B2 (ja) * 2011-03-01 2014-04-02 ジェン−プローブ・インコーポレーテッド 薬剤耐性突然変異と関連する配列検出のためのｈｉｖ−１配列の増幅
JP2012105648A (ja) * 2011-12-12 2012-06-07 Gen Probe Inc 薬剤耐性突然変異と関連する配列検出のためのｈｉｖ−１配列の増幅
CA2958402C (fr) * 2013-08-26 2021-02-02 The Royal Institution For The Advancement Of Learning / Mcgill University Agents a base de petit arn antisens ciblant le cadre de lecture ouvert gag de l'arn du vih-1

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014427A2 (fr) * 1989-05-25 1990-11-29 Sandoz Ltd Represseur polyvalent de fonctions geniques
EP0598935A1 (fr) * 1992-11-24 1994-06-01 Bayer Ag Vecteurs d'expression et leur utilisation pour la production de cellules humaines résistantes à HIV pour utilisation thérapeutique
EP0612844A2 (fr) * 1993-02-25 1994-08-31 Ortho Pharmaceutical Corporation Vecteurs d'expression contenant des antisens inhibiteurs d'HIV et d'autres séquences nucléotidiques, vecteurs rétroviraux et rétrovirus recombinants les contenant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014427A2 (fr) * 1989-05-25 1990-11-29 Sandoz Ltd Represseur polyvalent de fonctions geniques
EP0598935A1 (fr) * 1992-11-24 1994-06-01 Bayer Ag Vecteurs d'expression et leur utilisation pour la production de cellules humaines résistantes à HIV pour utilisation thérapeutique
EP0612844A2 (fr) * 1993-02-25 1994-08-31 Ortho Pharmaceutical Corporation Vecteurs d'expression contenant des antisens inhibiteurs d'HIV et d'autres séquences nucléotidiques, vecteurs rétroviraux et rétrovirus recombinants les contenant

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RENNEISEN K ET AL: "INHIBITION OF EXPRESSION OF HUMAN IMMUNODEFICIENCY VIRUS-1 IN VITRO BY ANTIBODY-TARGETED LIPOSOMES CONTAINING ANTISENSE RNA TO THE ENV REGION", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 27, 25 September 1990 (1990-09-25), pages 16337 - 16342, XP000148392 *
VANDENDRIESSCHE, T. ET AL.: "Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes", JOURNAL OF VIROLOGY., vol. 69, July 1995 (1995-07-01), AMERICAN SOCIETY FOR MICROBIOLOGY US, pages 4045 - 4052, XP002046632 *
WOFFENDIN, C. ET AL.: "Expression of a protective gene prolongs survival of T cells in human immunodeficiency virus-infected patients", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 93, April 1996 (1996-04-01), WASHINGTON US, pages 2889 - 2894, XP002046633 *

Also Published As

Publication number Publication date
AU3255897A (en) 1998-01-05
CA2254819A1 (fr) 1997-12-11
WO1997046673A2 (fr) 1997-12-11
AU717233B2 (en) 2000-03-23
IL127038A0 (en) 1999-09-22
NZ333190A (en) 2001-03-30
JP2001502884A (ja) 2001-03-06
EP0914423A2 (fr) 1999-05-12

Similar Documents

Publication Publication Date Title
WO1999046372A3 (fr) Ribozymes capables d'inhiber l'expression du recepteur ccr5
WO1996021731A3 (fr) Sequences guides externes stabilisees
HU9501963D0 (en) 7-deazapurine modified oligonucleotides
WO2001047944A3 (fr) Acides nucleiques contenant des polymorphismes mononucleotidiques et procedes d'utilisation correspondants
CA2359180A1 (fr) Methode et medicament destines a inhiber l'expression d'un gene donne
EP1165594A4 (fr) Modulation de l'expression des stat3, au moyen d'oligonucleotides antisens
EP2213736A3 (fr) Procédé d'inhibition de l'expression d'un gène cible et médicament destiné au traitement d'une maladie tumorale
EP1248794A4 (fr) Modulation antisens de l'expression de la proteine smad7
AU4595399A (en) Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues
EP1409509A4 (fr) Modulation antisens de l'expression de la proteine reactive c
AU2001258316A1 (en) Process for the fermentative preparation of l-threonine
AU6125296A (en) Oligonucleotides specific for hepatitis b virus
WO2002042422A3 (fr) Interactions moleculaires dans des cellules hematopoietiques
WO2000029623A3 (fr) Acides nucleiques contenant des polymorphismes d'un seul nucleotide et utilisations de ces acides nucleiques
WO1997046673A3 (fr) Inhibition de la replication du vih-1 au moyen de l'expression d'arn antisens
EP0775745A3 (fr) Aptamères capables d'inhiber la cathépsine G
EP1250347A4 (fr) Modulation antisens de l'expression de akt-3
WO1997009420A3 (fr) Codage de sequences d'adn destine a une metalloproteinase humaine et ses variants
MX9806041A (es) Proteina purificada sr-p70.
EP1163373A4 (fr) Modulation antisens de l'inhibiteur cellulaire de l'expression de l'apoptose-1
CA2316113A1 (fr) Methode de purification d'acide nucleique au moyen d'iode
EP1165145A4 (fr) Regulation antisens d'expression de mdmx
WO2001048245A3 (fr) Acides nucleiques contenant des polymorphismes de nucleotides simples, et procedes d'utilisation correspondants
WO2001040521A3 (fr) Acides nucleiques contenant des polymorphismes mononucleotidiques et procedes d'utilisation correspondants
AU6884596A (en) Systematic extraction, amplification and detection of retroviral sequences, and oligonucleotides for use therein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997928151

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2254819

Country of ref document: CA

Ref country code: CA

Ref document number: 2254819

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09194300

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 333190

Country of ref document: NZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997928151

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997928151

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载